

MAINE Diabetes Data & Forecasts

State Total Population Forecasts	2015	2020	2025	2030
Entire Population	1,388,900	1,408,700	1,414,400	1,411,100
Prediabetes	391,700	410,400	424,400	424,000
Diagnosed diabetes	120,500	144,700	163,400	176,000
Undiagnosed diabetes	40,400	46,100	49,300	50,400
Total with diabetes (diagnosed and undiagnosed)	160,900	190,800	212,700	226,400
Complications:				
Visual impairment	19,800	23,000	25,200	26,400
Renal failure	290	330	360	380
Leg amputations	250	280	290	280
Annual deaths attributable to diabetes	1,300	1,490	1,600	1,630
Total annual cost (2015 dollars)	\$1.9 B	\$2.3 B	\$2.5 B	\$2.7 B
Annual medical costs	\$1.4 B	\$1.7 B	\$1.8 B	\$2.0 B
Annual nonmedical costs	\$0.5 B	\$0.6 B	\$0.7 B	\$0.7 B

State Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	250,200	294,000	339,000	374,000
Prediabetes	127,600	149,900	172,900	190,700
Diagnosed diabetes	47,300	55,600	64,100	70,700
Undiagnosed diabetes	17,500	20,600	23,700	26,200
Total with diabetes (diagnosed and undiagnosed)	64,800	76,100	87,800	96,900
Complications:				
Visual impairment	8,800	10,100	11,400	12,200
Renal failure	150	170	180	200
Leg amputations	110	120	130	130
Annual deaths attributable to diabetes	900	1,000	1,040	1,030
Total annual cost (2015 dollars)	\$828 M	\$973 M	\$1.1 B	\$1.2 B
Annual medical costs	\$776 M	\$912 M	\$1.0 B	\$1.1 B
Annual nonmedical costs	\$52 M	\$61 M	\$0.1 B	\$0.1 B

These forecasts are based on the latest available national diabetes data, including U.S Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.